Literature DB >> 12193153

Erythropoietin and the brain: from neurodevelopment to neuroprotection.

M Buemi1, E Cavallaro, F Floccari, A Sturiale, C Aloisi, M Trimarchi, G Grasso, F Corica, N Frisina.   

Abstract

It is now widely known that erythropoietin (Epo) does not only affect the haematopoietic system, but it can be considered a multifunctional trophic factor with an effect on the general homoeostasis of the entire organism. The recent discovery of a specific Epo/Epo-receptor system in the central nervous system (CNS) and cerebrospinal fluid, independently of the haematopoietic system, has further paved the way for new studies aimed at investigating the different sites of cerebral expression of Epo and its receptor, the regulation of their expression and, finally, the effects that this hormone has on the development and maturation of the brain. A further aim has been to investigate how it influences CNS homoeostasis and neurotransmission in adult brain. Attention has also been focused on the neurotrophic and neuroprotective function of Epo in different conditions of neuronal damage, such as hypoxia, cerebral ischaemia and subarachnoid haemorrhage, and therefore on the possibility that human recombinant Epo therapy could soon be used in clinical practice, also to limit neuronal damage induced by these diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193153     DOI: 10.1042/cs1030275

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  22 in total

Review 1.  A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection.

Authors:  RuiRong Yuan; Bo Wang; Wei Lu; Yasuhiro Maeda; Peter Dowling
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 2.  Hypoxic preconditioning protects against ischemic brain injury.

Authors:  Frank R Sharp; Ruiqiong Ran; Aigang Lu; Yang Tang; Kenneth I Strauss; Todd Glass; Tim Ardizzone; Myriam Bernaudin
Journal:  NeuroRx       Date:  2004-01

3.  Erythropoietin Attenuates the Memory Deficits in Aging Rats by Rescuing the Oxidative Stress and Inflammation and Promoting BDNF Releasing.

Authors:  Zhankui Jia; Rui Xue; Shengli Ma; Jingjing Xu; Si Guo; Songchao Li; Erwei Zhang; Jun Wang; Jinjian Yang
Journal:  Mol Neurobiol       Date:  2015-10-20       Impact factor: 5.590

4.  Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Morteza Entezari; Zahra Kiani Flavarjani; Alireza Ramezani; Humayon Nikkhah; Saeed Karimi; Hamid Fateh Moghadam; Narsis Daftarian; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-10       Impact factor: 3.117

5.  Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats.

Authors:  Amalia Merelli; Laura Caltana; Patricia Girimonti; Alberto Javier Ramos; Alberto Lazarowski; Alicia Brusco
Journal:  Neurotox Res       Date:  2010-11-30       Impact factor: 3.911

6.  Evaluation of the therapeutic benefit of delayed administration of erythropoietin following early hypoxic-ischemic injury in rodents.

Authors:  M L Alexander; C A Hill; T S Rosenkrantz; R H Fitch
Journal:  Dev Neurosci       Date:  2013-01-10       Impact factor: 2.984

7.  Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Authors:  P Janik; H Kwiecinski; B Sokolowska; I Niebroj-Dobosz
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

8.  Safety of intravitreally administered recombinant erythropoietin (an AOS thesis).

Authors:  James C Tsai
Journal:  Trans Am Ophthalmol Soc       Date:  2008

9.  A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury.

Authors:  Alberto Pinzon; Alexander Marcillo; Diego Pabon; Helen M Bramlett; Mary Bartlett Bunge; W Dalton Dietrich
Journal:  Exp Neurol       Date:  2008-07-14       Impact factor: 5.330

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.